How do we overcome long acting injectable design hurdles?
Qrono’s briefing on Generic LAI development with QronoMetrics demonstrates how our technology can be economically applied to multiple candidates across your portfolio.
The new Qrono™ QARRUS™ program can help you overcome dose-related toxicity, a major threat to promising candidates. Review our QARRUS™ Case Study on epothilone D to see how we achieved optimal local chemotherapeutic levels over a 7-week duration—while reducing systemic toxicity by 80%.
FDA Awards Qrono™ 3-Year Contract
Qrono Awarded Three-Year Contract from Food and Drug Administration to Support Availability of Generic Long-Acting Medicines
The $612K contract will be used to design and construct physiologically-based pharmacokinetic models relating the critical quality attributes of long acting injectable microspheres to in vivo performance. [More…]
Qrono Delivers — Let’s talk about your formulation needs!
|Pharma R&D has only a limited window to demonstrate that promising compounds can be formulated to product specification. Yet most delivery technologies require successive iterations of design, in vitro and in vivo testing for formulation validation.||Experimentally-designed formulations with good in vitro results often behave differently in vivo. Or formulations that do pass clinical trials have consistency problems during manufacturing scale up. Qrono’s computational drug delivery technology can help you avoid or overcome these challenges.||Qrono has leveraged this technology to create a pipeline of new long-acting medicines with improved therapeutic and pharmacoeconomic benefits in anti-psychotics, infectious disease, oncology, endocrinology, and medical countermeasures.|